Opportunity
Simpler Grants.gov #RFA-AI-28-012
NIH Forecast: Cooperative Agreement for Human Microphysiologic Systems in Infectious Disease Research
Buyer
National Institutes of Health
Posted
June 24, 2026
Respond By
January 29, 2027
Identifier
RFA-AI-28-012
NAICS
541714, 541715
This opportunity is a forecasted cooperative agreement from the National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), to support the development of human microphysiologic systems (MPS) for infectious disease research and therapeutic development. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - OEMs and Vendors: - No specific OEMs or vendors are named; the solicitation is open to a broad range of organizations, including government, nonprofit, educational, and business entities - Products/Services Requested: - Development and advancement of human microphysiologic systems (MPS) - In vitro platforms composed of cells or tissues in microenvironments that mimic physiological aspects of in vivo tissue or organ function - Focus on infectious disease research and the development of therapeutics or biological products - Unique or Notable Requirements: - Accelerate the use of MPS in infectious disease studies and product development - Promote adoption by drug and biological product developers and regulatory acceptance - Opportunity is open to U.S. and non-U.S. entities - Estimated total funding is $7,000,000 with approximately five awards anticipated
Description
The National Institute of Allergy and Infectious Diseases (NIAID) is seeking to support the development of human microphysiologic systems (MPS) specifically for infectious disease research and the development of therapeutics or biological products. MPS are in vitro platforms designed to mimic physiological aspects of in vivo tissue or organ function. This program aims to accelerate the use of MPS in infectious disease studies and product development, promoting their adoption by drug and biological product developers and regulatory acceptance. The funding opportunity is a cooperative agreement with a total funding of $7,000,000 and expects to make 5 awards.